Emcutix Biopharmaceuticals Inks In-Licensing Deal with WiQo for Skin Treatment

New Delhi, Apr 1 (PTI) Emcutix Biopharmaceuticals Ltd, a wholly owned arm of Emcure Pharmaceuticals, on Tuesday said it has signed an exclusive in-licensing agreement with Italian derma-cosmetic and medical device firm WiQo.

Under the pact, Emcutix will have the rights to import, promote, distribute and sell WiQo's non-invasive skin treatment product PRX-PLUS in India, the company said in a statement.

PRX-PLUS has a feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience, it added.

Emcutix Biopharmaceuticals CEO Sathya Narayanan said PRX-PLUS is a unique and advanced skincare solution.

"With the strong marketing expertise of Emcutix, we are confident that PRX-PLUS will set new benchmarks in dermatological care, making cutting-edge skincare more accessible to consumers across India," he added.

WiQo CEO Cristian Dufeu said, "With PRX Plus, we are not only introducing an innovative, needle-free solution for skin tightening, but also empowering dermatologists and patients with a safer, more effective alternative in the ever-evolving world of aesthetic medicine. This collaboration is a testament to our commitment to bringing ground-breaking, science-backed innovations to new markets...